The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderate to severe active Crohn’s disease (CD). The approval marks the ...

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

Guselkumab is the first IL-23 inhibitor approved for Crohn's disease with subcutaneous and intravenous options, targeting inflammation by blocking IL-23 and binding to CD64. The GRAVITI study ...

Tremfya is the only IL-23 inhibitor with IV and SC induction options for treating Crohn disease. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of ...

If you have Crohn’s disease, the right medications may keep your condition under control. Some may even push your disease into remission, which means you won’t have any symptoms for a certain ...

March 24, 2025 – The FDA has approved a new Crohn’s disease treatment called guselkumab, which, unlike similar drugs, can be given via self-injection by patients at home, provided their ...

TREMFYA ® is the only IL-23i to show superiority versus STELARA ® in all pooled endoscopic endpoints within a double-blinded registrational trial TREMFYA ® approval in Crohn's disease ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...